Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Leukemia|April 1, 1994
Reversal of CAMAL-mediated alterations of normal and leukemic in vitro myelopoiesis using inhibitors of proteolytic activityH A Leitch, J G Levy
Canadian Family Physician Medecin De Famille Canadien|August 5, 2000
Necrotizing fasciitis secondary to group A streptococcus. Morbidity and mortality still highH A Leitch, A Palepu, C M Fernandes
Leukemia|September 1, 1993
Stimulation of leukemic myelopoiesis by P30-35 CAMAL, an inhibitor of normal myelopoiesisH A Leitch, N Buskard, J G Levy
Current Oncology (Toronto, Ont.)|November 23, 2018
Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indicationsS A Wong, B I Dalal, H A Leitch
Leukemia|May 1, 1993
Inhibition of murine hematopoiesis by CAMAL, an inhibitor of human hematopoiesisH A Leitch, S T Yip, C H Jamieson, et al.
Experimental Hematology|February 1, 1991
Purification of an in vitro inhibitor of normal myelopoiesis using a monoclonal antibody directed to a common antigen of myelogenous leukemia (CAMAL)J E Shellard, H A Leitch, P M Logan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Limited-stage mantle-cell lymphomaH A Leitch, R D Gascoyne, M Chhanabhai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysisJ Mangel, H A Leitch, J M Connors, et al.
Advances in Hematology|December 23, 2011
HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART EraJ A Rodrigo, L K Hicks, M C Cheung, et al.
HIV Clinical Trials|July 11, 2007
Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapyH Ezzat, D Filipenko, L Vickars, et al.
Pageof 2